Rautou Pierre-Emmanuel

Our results just published in @jclinicalinvest demonstrate that microvesicles derived from erythrocytes are responsible for cardiovascular events occurring in patients with myeloproliferative neoplasms. Congratulations to @poisson_johanne & the whole team @parcc_inserm @Inserm

🟠Lamentamos profundamente la pérdida del Dr. Jaume Bosch, que fue presidente de la #AEEH, primer director científico de #CIBERehd, figura central de la hepatología moderna, referente científico a nivel internacional y maestro de toda una generación de hepatólogos españoles.…

📢An overview on vascular involvement in chronic liver disease: pubmed.ncbi.nlm.nih.gov/40704070/ Everything on: ➡️ portal vein thrombosis ➡️ PSVD ➡️ haemostasis in cirrhosis ➡️ management of portal hypertension ➡️ challenges of TIPS ➡️ vascular consequences of cirrhosis (PoPH, HPS, AKI)

🔥 We’ve hit 50% recruitment in the #COMBATtrial! Huge thanks to all involved!💙 @RautouE @ef_clif @hospitalclinic @LiverIcu @UniklinikAachen @Unibo @Zac_MD @DrAAlbillos @unito @VHIR_ @APHP @UK_Muenster @MEDB_LAB @UschnerFrank @rajmookerjee #LiverTwitter #ACLF #ClinicalTrials

🚨 New #ReadOfTheWeek on the prognostic value of residual ascites post-TIPS 👉Cohort: 292 patients with cirrhosis, stratified by #ascites grade at 3 months (36% none; 28% minimal; 36% mod/sev) 👉 Minimal ascites independently predicted:  🔎further decompensation (aSHR 1.76;…

🎥 New keynote online! Prof. Richard Moreau, Director of @ef_clif, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency. Watch now 👉 youtu.be/KWoUbTsNjQM #LiverTwitter #Hepatology

Hepatology papers #livertwitter, someone had to do it

Catch up on this week's #EASLStudio and find out what's new in the recently published CPGs on vascular liver diseases! 🔗 easlcampus.eu/videos/easl-st… @RautouE #LiverTwitter #LiverX

I’m very proud to share with you the 2024 IF of the Journal of Hepatology. I want to thank the members of the Office, the Editors, the Reviewers, the Authors and the Readers for this great achievement.

🎬 Alas, EASL Studio Season 8 has come to a close. A huge thank you to all the faculty for the insightful discussions this season! 💻 Missed an episode? Catch up on demand via EASL Campus. 🎧 Prefer audio? Tune in on Spotify (with video!), Apple Music, and Amazon Music. 🌞 We’ll…

🔴#EASLStudio is now LIVE! We’re discussing the upcoming EASL Guidelines on Vascular Liver Disease – set to be published later this year. Join the conversation with our expert panel ⬇️ easl.eu/easl-studio-ep… @Jhepatology @EASLNews @RautouE @jcgarciapagan @BavenoCoop…

Should we treat all cirrhosis patients with anticoagulants to prevent PVT? Not yet, evidence is limited. ➡️ Some studies (Rivaroxaban, Enoxaparin) suggest benefit ➡️ Potential to reduce complications & decompensation But more data is needed before a general recommendation.…

Who should receive anticoagulation in cirrhosis with PVT? Liver transplant candidates: Treat progressive PVT Non-candidates:Treat if >50% lumen occlusion <50%: Consider surveillance or treatment on a case-by-case basis ⚖️ Decision based on extent, progression, and transplant…

Should we screen for thrombosis risk factors in cirrhosis? NO. 🔹Studies show no added PVT risk from inherited thrombophilia 🔹PVT in cirrhosis is more linked to low portal inflow & local wall stress ➡️ Thrombophilia screening not routinely recommended. @Jhepatology @EASLNews…

Portal Vein Thrombosis (PVT) in cirrhosis, what do we know? 👉#MASLD is a leading cause of #PVT 👉#Cirrhosis increases PVT risk, regardless of aetiology 👉Risk persists despite treatment in some cases (e.g. HCV) @Jhepatology @EASLNews @RautouE @jcgarciapagan @BavenoCoop…

Managing PVT + non-invasive HCC in cirrhosis? ✅ Lower threshold for anticoagulation - even with <50% occlusion ⚠️ Ensure it's not tumoural thrombosis before initiating treatment! @Jhepatology @EASLNews @RautouE @jcgarciapagan @BavenoCoop @DebbieShawcros1 #EASLStudio #LiverX

What kind of anticoagulant should be used in cirrhosis? DOACs? Maybe. But… 🟢Child-Pugh A: Yes 🟠 Child-Pugh B: Caution 🔴 Child-Pugh C: Not recommended ⚠️Watch INR levels ⚠️In transplant setting: Prefer low molecular weight heparins @Jhepatology @EASLNews @RautouE…

TIPS and PVT, what’s the risk? 🤔 Will the clot go to the lung? Rarely. TIPS is complex (10% complication rate), bleeding most common. ➡️ Routine anticoagulation post-TIPS? Not recommended. 📊 Depends on individual PVT pathophysiology. @Jhepatology @EASLNews @RautouE…

Best anticoagulation approach in portal cavernoma? 👉Depends on cause of PVT 👉Always identify fibronoma at first presentation 👉High-risk patients (e.g. thrombophilia, family history): Treat 👉Low recurrence → multidisciplinary decision @Jhepatology @EASLNews @RautouE…

Splenic artery (true) aneurysm vs pseudoaneurysm True: All 3 layers, mostly splenic, may be genetic Pseudo: Outer wall only, trauma/infection-related 🔺 Pseudo: Always treat 🔺 True: Treat based on size/risk (e.g. >2–2.5 cm, pregnant, transplant setting) @Jhepatology @EASLNews…

#LiverX, are you ready for the #EASLStudio season 8 finale tomorrow? We’ll be exploring the upcoming EASL Clinical Practice Guidelines on vascular liver diseases. ▶️ PVT in cirrhosis & non-cirrhosis ▶️ DOACs, TIPS & CIRROXABAN insights ▶️ Splanchnic artery aneurysms @Jhepatology…